NCT07069699View on ClinicalTrials.gov

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

September 19, 2027

Study Completion Date

September 19, 2027

Conditions
Burkitt LymphomaDouble-Expressor LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Interventions
PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo CSF and blood sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT scan

PROCEDURE

Lumbar Puncture

Undergo lumbar puncture

DRUG

Pidnarulex

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT07069699 - Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene | Biotech Hunter | Biotech Hunter